HOME > Articles >

Korean J Gastroenterol  <  Volume 47(6); 2006 <  Articles

Korean J Gastroenterol 2006; 47(6): 413-419  
과민성 장증후군 환자에서 생균제의 효과
김영균 ( Young Gyun Kim ) , 문종태 ( Jong Tae Moon ) , 이근만 ( Kuen Man Lee ) , 전누리 ( Nu Ri Chon ) , 박효진 ( Hyo Jin Park )
Published online: June 25, 2006.
© The Korean Journal of Gastroenterology. All rights reserved.

This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Background/Aims: Irritable bowel syndrome (IBS) is a functional gastrointestinal (GI) tract disorder that has heterogeneous clinical presentations such as abdominal pain, diarrhea, constipation, and abdominal distension. It is known that several mechanisms are involved in the pathogenesis of IBS. Probiotics may target one or more pathophysiologic pathways in IBS and may improve the symptoms of IBS. However, the results of studies about probiotics on IBS are controversial. Therefore, the aim of this study was to evaluate the effect of probiotics on GI symptoms and intestinal gas volume changes in patients with IBS. Methods: Forty patients were randomly allocated to be treated with medilac DS(R) (Bacillus subtilis, Streptococcus faecium) (n=20) or placebo (n=20) in a double-blind, prospective manner. The change in intestinal gas volume and symptom scores after 4-week treatment were evaluated for the efficacy. Results: There was no significant difference in bloating, frequency of gas expulsion, frequency of defecation, and hardness of stool before and after the treatment. However, the severity of abdominal pain and the frequency of abdominal pain decreased significantly in medilac DS(R) group (2.4±1.3 cm/ day→1.6±1.6 cm/day, 1.7±1.3/day→1.0±1.0/day) (p=0.044, p=0.038), but not in placebo group (2.1±2.0 cm/day →1.8±2.1 cm/day, 1.3±1.2/day→1.4±1.9/day). In both groups, intestinal gas volume at baseline, after 2-week treatment, and after 4-week treatment did not show significant change. Medilac DS(R) was well tolerated without adverse events. Conclusions: Medilac DS(R) is a safe and useful probiotic agent for the treatment of abdominal pain in patients with IBS. (Korean J Gastroenterol 2006;47:413-419)
Keywords: 생균제, 과민성 장증후군, Probiotics, Bacillus subtilis, Streptococcus faecium, Irritable bowel syndrome

This Article


Stats or Metrics
  • View: 123
  • Download: 384

Services

Social Network Service

e-submission

Archives

Official Journal of

Indexed/Covered by

  • esci
  • scopus
  • thomson reuters
  • koreamed
  • crossref
  • google
  • synepse
  • kofst
  • DOAJ
  • ORCID